A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Other illness

• Patient with another cancer concomitantly with the mCRC requiring treatment or influencing the prognosis according to the medical staff.
• Any condition that may jeopardize patient participation in the study as well as non-contraception for men and women with child-bearing potential, and pregnancy or breast feeding for women.

Other

• Patients for whom the follow-up will not be assured by the investigator or its team.
• Persons deprived of their liberty or under protective custody or guardianship.

• Men and women aged 18 years or older
• Histologically confirmed BRAFV600E metastatic colorectal cancer (mCRC), chemotherapy-naive in the metastatic setting or having initiated a first line of chemotherapy in the metastatic setting (except encorafenib-cetuximab treatment)
• Available tumor tissue sample obtained before inclusion with sufficient tissue left for biological studies. Patients with only fine-needle aspirations are not eligible.
• Known MMR/microsatellite status (immunohistochemistry \[IHC\] and polymerase chain reaction \[PCR\]) (or under analysis)
• Patients must have signed a written informed consent form prior to any trial specific procedures. If the patients are physically unable to give their written consent, a trusted person of their choice, not related to the investigator or the sponsor, can confirm in writing the patient's consent.
• Patients must be willing and able to comply with the study procedures
• The patient must be affiliated to a social security system or benefit of such a system.